Sepsis severely compromises medical progress and consumes a major part of all health care resources. However, the last decades saw no critical developments concerning diagnosis of the disease or the pathogen nor any developments in the therapeutic field.
Early indications for sepsis which result from a decreased oxygen supply of the organs could be:
These signs are sensitive but unspecific, they can be found in many patients with other diseases. Therefore, an early diagnosis of sepsis is difficult. Furthermore, the identification of the pathogen is time-consuming and complicated. However, patient's survival relies on an early sepsis diagnosis, a fast and precise identification of the pathogen as well as individual therapy.
Since the 1980s, citizens of industrial countries suffer more and more from sepsis. In most cases, bacterial infections are the triggering cause; however, fungal infections are increasing in significance.
The costs for treating severe sepsis average 58,000 euros per patient. Thus, that treatment of acute sepsis (in total around five billion euros per year) exhausts a substantial portion of the overall intensive care budget in Germany.
Worldwide, there is a strong demand for new products to diagnose and treat sepsis. To meet this demand, it is essential to gain a better understanding of the disease on the molecular level. Thus, an effective research strategy must adopt an integrated approach aimed at achieving
The basics for this are laid by Septomics' research work.